摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(4-methoxyphenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

中文名称
——
中文别名
——
英文名称
5-(4-methoxyphenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
英文别名
5-(4-methoxyphenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one;5-(4-methoxyphenyl)-1-methyl-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-7-one
5-(4-methoxyphenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one化学式
CAS
——
化学式
C16H18N4O2
mdl
——
分子量
298.345
InChiKey
BUFJCQZXYNSWBG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    68.5
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    二苯基乙炔5-(4-methoxyphenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 在 [ruthenium(II)(η6-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]2potassium acetate 作用下, 以 甲醇氯仿 为溶剂, 反应 1.04h, 以89%的产率得到3-methoxy-9-methyl-5,6-diphenyl-11-propylpyrazolo[4',3':4,5]pyrimido[2,1-a]isoquinolin-8(9H)-one
    参考文献:
    名称:
    用于融合 N-杂芳基支架合成和吡唑并吡啶后期功能化的微光流反应器系统
    摘要:
    活性药物成分的后期功能化 (LSF) 可以为结构活性关系研究 (SARS) 的药物分子的有效从头设计和合成提供一种直接的方法。在此,我们开发了一种可见光驱动的模块化微流反应器,该反应器由一个集成的后合成后处理组成,该反应器旨在合成融合的 N-杂芳基支架和吡唑并吡啶的后期功能化,而无需使用任何昂贵的氧化剂或额外的光催化剂 (PC)。
    DOI:
    10.1039/d2cc03713k
  • 作为产物:
    参考文献:
    名称:
    [EN] PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE AND PROCESS FOR THE PREPARATION THEREOF
    [FR] PYRAZOLOPYRIMIDINONES POUR LE TRAITEMENT DE L'IMPUISSANCE ET PROCÉDÉ DE PRÉPARATION CORRESPONDANT
    摘要:
    本发明涉及作为PDE5抑制剂的吡唑嘧啶酮化合物,具有更好的IC50值、良好的体内有效性和PK特性,以及其制备方法。本发明涵盖基于吡唑嘧啶酮的化合物,这些化合物已经被设计、合成和筛选用于PDE5抑制活性,其PDE5抑制潜力在本发明中提供。这些设计的化合物在筛选PDE5抑制活性时表现出纳摩尔级的效力,并且在体内表现出更好的有效性。这些化合物可以用于治疗男性勃起功能障碍或阳痿的治疗。
    公开号:
    WO2015114647A1
点击查看最新优质反应信息

文献信息

  • A facile one step synthesis of 1,6 -dihydro-7<i>H</i>-pyrazolo[4,3-<i>d</i>]-pyrimidin-7-ones
    作者:Nalla Ram Reddy、Ghanta Mahesh Reddy、Battu Saida Reddy、Padi Pratap Reddy
    DOI:10.1002/jhet.5570420502
    日期:2005.7
    A general synthetic approach to pyrazolo[4,3-d]pyrimidines is reported. Aldehydes, arylideneanilines, carboxylic acids and orthoesters are used as one-carbon units for bridging the two amino functions of 4-amino-1-alkyl-3-propylpyrazole-5-carboxamides.
    报道了吡唑并[4,3- d ]嘧啶的一般合成方法。醛,芳基苯胺羧酸和原酸酯用作连接4-基-1-烷基-3-丙基吡唑-5-羧酰胺的两个基官能团的一个碳单元。
  • A modified, economical and efficient synthesis of variably substituted pyrazolo[4,3-<i>d</i>]pyrimidin-7-ones
    作者:Khalid Mohammed Khan、Ghulam Murtaza Maharvi、Muhammad Iqbal Choudhary、Atta-ur- Rahman、Shahnaz Perveen
    DOI:10.1002/jhet.5570420608
    日期:2005.9
    treated with various aroyl amides under microwave (MW) irradiation to afford 4-aroylamino-1-methyl-3-propyl-1H-pyrazole-5-carboxamides 10-22 and 5-aryl-1-methyl-3-propyl-1,6-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-ones 23-35. The 1H-pyrazole-5-carboxamides 10-22 were also converted to pyrimidinones 23-35 either by conventional heating or by MW irradiation. However, MW irradiation method gives excellent yields
    1-甲基-3-丙基-1 H-唑-5-羧酸(3)在黑暗中仅在4位被化。然后通过依次用亚硫酰氯和氢氧化处理,将化产物8转化为1-甲基-3-丙基-1 H-吡唑-5-羧酰胺9。在微波(MW)照射下,用各种芳基酰胺处理羧酰胺9,得到4-芳酰基基-1-甲基-3-丙基-1 H-吡唑-5-羧酰胺10-22和5-芳基-1-甲基-3-丙基-1,6-二氢-1 H-吡唑并[4,3 - d ]嘧啶-7-酮23-35。1小时通过常规加热或通过MW辐射,也将-吡唑-5-羧酰胺10-22转化为嘧啶酮23-35。但是,MW辐照法可在很短的时间内提供极好的收率。
  • Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof
    申请人:COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    公开号:US10017511B2
    公开(公告)日:2018-07-10
    The present invention relates to Pyrazolopyrimidinone compounds as PDE5 inhibitors with better IC50 value, good in vivo efficacy and PK profile and a process for the preparation thereof. The present invention covers the pyrazolo pyrimidinone based compounds that have been designed, synthesized and screened for PDE5 inhibitory activity and its PDE5 inhibitory potential is provided in this invention. These designer compounds have shown nanomolar potency when screened for PDE5 inhibitory activity and also shown better in vivo efficacy. These compounds can be used in the treatment of male erectile dysfunction or in the treatment of impotence.
    本发明涉及吡唑嘧啶酮类化合物作为PDE5抑制剂,具有较好的IC50值、良好的体内疗效和PK谱及其制备工艺。本发明涵盖了经过设计、合成和筛选的具有 PDE5 抑制活性的吡唑嘧啶酮类化合物,本发明提供了其 PDE5 抑制潜力。这些设计化合物在进行 PDE5 抑制活性筛选时显示出纳摩尔效力,并显示出较好的体内疗效。这些化合物可用于治疗男性勃起功能障碍或阳痿。
  • Synthesis of 5-substituted-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one analogs and their biological evaluation as anticancer agents: mTOR inhibitors
    作者:G. Lakshma Reddy、Santosh Kumar Guru、M. Srinivas、Anup Singh Pathania、Priya Mahajan、Amit Nargotra、Shashi Bhushan、Ram A. Vishwakarma、Sanghapal D. Sawant
    DOI:10.1016/j.ejmech.2014.04.051
    日期:2014.6
    A microwave assisted strategy for synthesis of series of 1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones has been developed and their biological evaluation as anticancer agents is described. The synthetic protocol involves simple procedure by oxidative coupling of 4-amino-1-methyl-3-propyl-1H-pyrazole-5-carboxamide with different aldehydes in presence of K2S2O8 offering 5-substituted-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-one compounds in excellent yields. The in vitro anticancer activity screening against human cancer cell lines HeLa, CAKI-I, PC-3, MiaPaca-2, A549 gave good results. The in detailed mechanistic correlation studies of compound 3m revealed that the compound shows anticancer activity through apoptosis mechanism and also inhibits mTOR with nonomolar potency. The design was based on docking with mTOR protein. The concentration dependent cell cycle analysis, western blotting experiment and nuclear cell morphology studies have been described.
  • InCl3-catalysed synthesis of 2-aryl quinazolin-4(3H)-ones and 5-aryl pyrazolo[4,3-d]pyrimidin-7(6H)-ones and their evaluation as potential anticancer agents
    作者:Naveen Mulakayala、Bhaskar Kandagatla、Ismail、Rajesh Kumar Rapolu、Pallavi Rao、Chaitanya Mulakayala、Chitta Suresh Kumar、Javed Iqbal、Srinivas Oruganti
    DOI:10.1016/j.bmcl.2012.06.003
    日期:2012.8
    A convenient and practical methodology for the synthesis of 2-aryl quinazolin-4(3H)-ones by the condensation of o-aminobenzamides with aromatic aldehydes under mild conditions using catalytic InCl3 with good yields and high selectivities. This method has been extended for the synthesis of 5-aryl pyrazolo[4,3-d]pyrimidin-7(6H)-ones which have potential applications in medicinal chemistry. Many of these compounds were evaluated for their anti-proliferative properties in vitro against four cancer cell lines and several compounds were found to be active. Further in vitro studies indicated that inhibition of sirtuins could be the possible mechanism of action of these molecules. (C) 2012 Elsevier Ltd. All rights reserved.
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 西地那非-嘧啶酮杂质 苯甲腈,4-(5-甲基-1,3-噁噻戊环-2-基)-(9CI) 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 羟基氯地那非 磷酸二氢2-甲氧基-5-[(Z)-2-(3,4,5-三甲氧苯基)乙烯基]苯酯 盐(1:?)1,3,5-萘三磺酸,7-[2-[4-[[5-氯-6-甲基-2-(甲磺酰)-4-嘧啶基]氨基]苯基]二氮烯基]-,钠 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基(1R,2S,4S)-2,5,7-三羟基-6,11-二羰基-2-(2-羰基丙基)-4-{[2,3,6-三脱氧-4-O-(2,6-二脱氧-α-L-来苏-六吡喃糖基)-3-(二甲氨基)-α-L-来苏-六吡喃糖基]氧代}-1,2,3,4,6,11-六氢四省-1-羧酸酯 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氯化[4-[(4-氯苯基)氰基甲基]-5-氯-m-苯甲基]铵 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 昔多芬杂质 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 噁庚并[3,4-c]吡啶-3,9-二酮,5-乙基-1,4,5,8-四氢-5-羟基-,(5R)- 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸,3-氰基-4,7-二氢-7-羰基-,甲基酯 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-7-羧酸 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 卡巴地那非 别嘌醇 别嘌呤醇D2 依鲁替尼杂质37